Terms: = Colorectal cancer AND CDX2, CDX3, 1045, ENSG00000165556, Q99626 AND Treatment
105 results:
1. Molecular Deciphering of colorectal cancer: Exploring Molecular Classifications and Analyzing the Interplay among Molecular Biomarkers MMR/MSI, KRAS, NRAS, BRAF and cdx2 - A Comprehensive Literature Review.
Ilie-Petrov AC; Cristian DA; Diaconescu AS; Chitul A; Blajin A; Popa A; Mandi DM; Negreanu R; Vieru C; Vrîncianu R; Ardeleanu CM
Chirurgia (Bucur); 2024 Apr; 119(2):136-155. PubMed ID: 38743828
[No Abstract] [Full Text] [Related]
2. Renin-Angiotensin Inhibitor, Captopril, Attenuates Growth of Patient-Derived colorectal Liver Metastasis Organoids.
Riddiough GE; Fifis T; Muralidharan V; Christophi C; Tran BM; Perini MV; Vincan E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542253
[TBL] [Abstract] [Full Text] [Related]
3. Multivariate Prognostic Models for Patients with Stages I and Ii Colon Carcinoma: a Strobe-Compliant Retrospective Cohort Study.
Oñate-Ocaña LF; Herrera-Goepfert R; Avilés-Salas A; Cortés CC; González-Trejo S; Carrillo JF; Ruiz-García E; Ochoa-Carrillo FJ; Aiello-Crocifoglio V; García-Cuellar CM
Rev Invest Clin; 2023; 75(5):259-271. PubMed ID: 37918013
[TBL] [Abstract] [Full Text] [Related]
4. Mucinous adenocarcinoma arising from a complex perianal fistula: a diagnostic and therapeutic challenge.
Hernández Alonso R; Soto Sánchez A; Camarasa Pérez Á; Hernández Hernández G; Barrera Gómez M
Rev Esp Enferm Dig; 2024 Jul; 116(7):387-389. PubMed ID: 37882163
[TBL] [Abstract] [Full Text] [Related]
5. The prognostic potential of cdx2 in colorectal cancer: Harmonizing biology and clinical practice.
Badia-Ramentol J; Gimeno-Valiente F; Duréndez E; Martínez-Ciarpaglini C; Linares J; Iglesias M; Cervantes A; Calon A; Tarazona N
Cancer Treat Rev; 2023 Dec; 121():102643. PubMed ID: 37871463
[TBL] [Abstract] [Full Text] [Related]
6. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon cancer: Multicenter Real-Life Data.
Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
[TBL] [Abstract] [Full Text] [Related]
7. cdx2-positive cancer of Unknown Primary With Upper-body Paralysis Was Dramatically Improved by colorectal cancer Chemotherapy.
Akagi H; Tanaka Y; Wada K; Takahashi M; Yoshida K; Domoto H
Anticancer Res; 2023 Jun; 43(6):2879-2884. PubMed ID: 37247890
[TBL] [Abstract] [Full Text] [Related]
8. Molecular profiling of colorectal cancer in a genetically admixed Hispanic population.
Montes-Rodríguez IM; Centeno-Girona H; Rivera-Lynch C; Rivera N; Cruz-Correa M
Cancer Med; 2023 May; 12(10):11686-11702. PubMed ID: 37039257
[TBL] [Abstract] [Full Text] [Related]
9. CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors.
Ziranu P; Pretta A; Pozzari M; Maccioni A; Badiali M; Fanni D; Lai E; Donisi C; Persano M; Gerosa C; Puzzoni M; Bardanzellu F; Ambu R; Pusceddu V; Dubois M; Cerrone G; Migliari M; Murgia S; Spanu D; Pretta G; Aimola V; Balconi F; Murru S; Faa G; Scartozzi M
Sci Rep; 2023 Mar; 13(1):4397. PubMed ID: 36928082
[TBL] [Abstract] [Full Text] [Related]
10. Urachal carcinoma: The journey so far and the road ahead.
Kumar R; Harilal S; Abdelgawad MA; Ghoneim MM; Kumar A; Mathew B
Pathol Res Pract; 2023 Mar; 243():154379. PubMed ID: 36821941
[TBL] [Abstract] [Full Text] [Related]
11. Fistula-Associated Anal Adenocarcinoma: A 20-Year Single-Center Experience.
Harpain F; Dawoud C; Wimmer K; Schlager L; Kirchnawy S; Rizk D; Girgis K; Mittermair E; Oberndorfer F; Wöran K; Riss S; Stift A; Stift J
Ann Surg Oncol; 2023 Jun; 30(6):3517-3527. PubMed ID: 36757514
[TBL] [Abstract] [Full Text] [Related]
12. The first comprehensive genomic characterization of rectal squamous cell carcinoma.
Astaras C; De Vito C; Chaskar P; Bornand A; Khanfir K; Sciarra A; Letovanec I; Corro C; Dietrich PY; Tsantoulis P; Koessler T
J Gastroenterol; 2023 Feb; 58(2):125-134. PubMed ID: 36357817
[TBL] [Abstract] [Full Text] [Related]
13. colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution.
Chen G; Gong T; Wang Z; Wang Z; Lin X; Chen S; Sun C; Zhao W; Kong Y; Ai H; Yang H; Liu Y; Wu F; Kang J; Zhao S; Xiao X; Sun J; He A; Li Z
Cell Oncol (Dordr); 2022 Dec; 45(6):1155-1167. PubMed ID: 36136268
[TBL] [Abstract] [Full Text] [Related]
14. Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Lim EA; Bendell JC; Falchook GS; Bauer TM; Drake CG; Choe JH; George DJ; Karlix JL; Ulahannan S; Sachsenmeier KF; Russell DL; Moorthy G; Sidders BS; Pilling EA; Chen H; Hattersley MM; Das M; Kumar R; Pouliot GP; Patel MR
Clin Cancer Res; 2022 Nov; 28(22):4871-4884. PubMed ID: 36044531
[TBL] [Abstract] [Full Text] [Related]
15. Oligometastatic deposits of prostate cancer found within the sigmoid pericolic fat that was resected for colonic adenocarcinoma: a case report.
Naumann DN; Hejmadi RK; Richardson JJR
J Med Case Rep; 2022 Jun; 16(1):221. PubMed ID: 35659714
[TBL] [Abstract] [Full Text] [Related]
16. Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating cdx2 expression.
Yu J; Yang K; Zheng J; Zhao P; Xia J; Sun X; Zhao W
Cell Death Dis; 2022 Apr; 13(4):388. PubMed ID: 35449124
[TBL] [Abstract] [Full Text] [Related]
17. [Progress in pulmonary enteric adenocarcinoma].
Zuo Y; Bai H; Ying JM; Wang J
Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):321-325. PubMed ID: 35448919
[TBL] [Abstract] [Full Text] [Related]
18. Current Perspectives on the Importance of Pathological Features in Prognostication and Guidance of Adjuvant Chemotherapy in Colon cancer.
Chen K; Wang H; Collins G; Hollands E; Law IYJ; Toh JWT
Curr Oncol; 2022 Feb; 29(3):1370-1389. PubMed ID: 35323316
[TBL] [Abstract] [Full Text] [Related]
19. cdx2 Biomarker Testing and Adjuvant Therapy for Stage II Colon cancer: An Exploratory Cost-Effectiveness Analysis.
Alarid-Escudero F; Schrag D; Kuntz KM
Value Health; 2022 Mar; 25(3):409-418. PubMed ID: 35227453
[TBL] [Abstract] [Full Text] [Related]
20. Pathological Features and Prognostication in colorectal cancer.
Chen K; Collins G; Wang H; Toh JWT
Curr Oncol; 2021 Dec; 28(6):5356-5383. PubMed ID: 34940086
[TBL] [Abstract] [Full Text] [Related]
[Next]
